SPK-241
N/A
Report date: 2023/02/11 20:39:11
NME
Base Information
Drug NameSPK-241
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKirin Holdings Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesDara Therapeutics IncBarbara Ann Karmanos Cancer InstituteNational Cancer Institute
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A